var title_f8_39_8816="Wrist flexion";
var content_f8_39_8816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Wrist flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8816=[""].join("\n");
var outline_f8_39_8816=null;
var title_f8_39_8817="High-fiber diet";
var content_f8_39_8817=[" <h1 id=\"patTopicTitle\">",
"  Patient information: High-fiber diet (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/39/8817/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/39/8817/contributors\" id=\"au721\">",
"       Arnold Wald, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/39/8817/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/39/8817/contributors\" id=\"se5582\">",
"       Timothy O Lipman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/39/8817/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/39/8817/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?8/39/8817?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIGH-FIBER DIET OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Eating a diet that is high in fiber has many potential health benefits, including a decreased risk of heart disease, stroke, and type 2 diabetes. Because high-fiber foods may be healthy for reasons other than their fiber content, the research has not always been able to determine if fiber is the healthful component. A high-fiber diet is a commonly recommended treatment for digestive problems, such as constipation, diarrhea, and hemorrhoids, although individual results vary widely, and the scientific evidence supporting these recommendations is weak.",
"    </p>",
"    <p>",
"     Fiber is normally found in beans, grains, vegetables, and fruits. However, most people do not eat as much fiber as is commonly recommended. This topic discusses what fiber is, why it is helpful, and how to increase dietary fiber.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS FIBER?",
"     </span>",
"    </p>",
"    <p>",
"     There is no single dietary \"fiber.\" Traditionally, fiber was considered that substance found in the outer layers of grains or plants and which was not digested in the intestines. Wheat bran, the outer layer of wheat grain, fit this model. We now know that \"fiber\" actually consists of a number of different substances. The term \"dietary fiber\" includes all of these substances and is now considered a better term than just \"fiber.\"",
"    </p>",
"    <p>",
"     Most dietary fiber is not digested or absorbed, so it stays within the intestine where it modulates digestion of other foods and affects the consistency of stool. There are two types of fiber, each of which is thought to have its own benefits:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Soluble fiber consists of a group of substances that is made of carbohydrates and dissolves in water. Examples of foods that contain soluble fiber include fruits, oats, barley, and legumes (peas and beans).",
"      </li>",
"      <li>",
"       Insoluble fiber comes from plant cells walls and does not dissolve in water. Examples of foods that contain insoluble fiber include wheat, rye, and other grains. The traditional fiber, wheat bran, is a type of insoluble fiber.",
"      </li>",
"      <li>",
"       Dietary fiber is the sum of all soluble and insoluble fiber.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BENEFITS OF A HIGH-FIBER DIET",
"     </span>",
"    </p>",
"    <p>",
"     The health effects of a high-fiber may depend to some extent on the type of fiber eaten. However, the difference between the health effects of two types of fiber are not very clear and may vary between individuals, so many providers encourage adding fiber in whatever way is easiest for the patient.",
"    </p>",
"    <p>",
"     There are several potential benefits of eating a diet with high-fiber content:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Insoluble fiber (wheat bran, and some fruits and vegetables) has been recommended to treat digestive problems such as constipation, hemorrhoids, chronic diarrhea, and fecal incontinence. Fiber bulks the stool, making it softer and easier to pass. Fiber helps the stool pass regularly, although it is not a laxative. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"        \"Patient information: Constipation in adults (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=see_link\">",
"        \"Patient information: Hemorrhoids (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"        \"Patient information: Chronic diarrhea in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Soluble fiber (psyllium, pectin, wheat dextrin, and oat products) can reduce the risk of coronary artery disease and stroke by 40 to 50 percent (compared to a low fiber diet) [",
"       <a class=\"abstract\" href=\"UTD.htm?8/39/8817/abstract/1,2\">",
"        1,2",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Soluble fiber can also reduce the risk of developing type 2 diabetes. In people who have diabetes (type 1 and 2), soluble fiber can help to control blood glucose levels.",
"      </li>",
"      <li>",
"       It is not clear if a high-fiber diet is beneficial for people with irritable bowel syndrome or diverticulosis. Fiber may be helpful for some people with these diagnoses while it may worsen symptoms in others.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HOW MUCH FIBER DO I NEED?",
"     </span>",
"    </p>",
"    <p>",
"     The recommended amount of dietary fiber is 20 to 35 grams per day. By reading the nutrition label on packaged foods, it is possible to determine the number of grams of dietary fiber per serving (",
"     <a class=\"graphic graphic_figure graphicRef51585 \" href=\"UTD.htm?38/31/39413\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Dietary sources of fiber",
"     </span>",
"     &nbsp;&mdash;&nbsp;The fiber content of many foods, including fruits and vegetables, is available in the table (",
"     <a class=\"graphic graphic_table graphicRef52349 \" href=\"UTD.htm?28/61/29661\">",
"      table 1",
"     </a>",
"     ). Breakfast cereals can be a good source of fiber. Some fruits and vegetables are particularly helpful in treating constipation, such as prunes and prune juice.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Other sources of fiber",
"     </span>",
"     &nbsp;&mdash;&nbsp;For those who do not like high-fiber foods such as fruits, beans, and vegetables, a good source of fiber is unprocessed wheat bran; one to two tablespoons can be mixed with food. One tablespoon of wheat bran contains approximately 1.6 grams of fiber.",
"    </p>",
"    <p>",
"     In addition, a number of fiber supplements are available. Examples include psyllium, methylcellulose, wheat dextrin, and calcium polycarbophil. The dose of the fiber supplement should be increased slowly to prevent gas and cramping, and the supplement should be taken with adequate fluid. The fiber in these supplements is mostly of the soluble type.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      FIBER SIDE EFFECTS",
"     </span>",
"    </p>",
"    <p>",
"     Adding fiber to the diet can have some side effects, such as abdominal bloating or gas. This can sometimes be minimized by starting with a small amount and slowly increasing until stools become softer and more frequent.",
"    </p>",
"    <p>",
"     However, many people, including those with irritable bowel syndrome, cannot tolerate fiber supplements and do better by not increasing fiber in their diet. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804382514\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2530845991\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/50/38690?source=see_link\">",
"      Patient information: Fecal incontinence (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/60/27586?source=see_link\">",
"      Patient information: Rectal prolapse in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=see_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2530846056\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=see_link\">",
"      Patient information: Hemorrhoids (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"      Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"      Healthy diet in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/dietaryfiber.html\">",
"      www.nlm.nih.gov/medlineplus/dietaryfiber.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute on Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Harvard School of Public Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hsph.harvard.edu/nutritionsource/what-should-you-eat/fiber/index.html\">",
"      www.hsph.harvard.edu/nutritionsource/what-should-you-eat/fiber/index.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?8/39/8817/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?8/39/8817?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8817/abstract/1\">",
"      Gillman MW, Cupples LA, Gagnon D, et al. Protective effect of fruits and vegetables on development of stroke in men. JAMA 1995; 273:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8817/abstract/2\">",
"      Jensen MK, Koh-Banerjee P, Hu FB, et al. Intakes of whole grains, bran, and germ and the risk of coronary heart disease in men. Am J Clin Nutr 2004; 80:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8817/abstract/3\">",
"      Negri E, Franceschi S, Parpinel M, La Vecchia C. Fiber intake and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8817/abstract/4\">",
"      Willett WC. Diet and cancer: an evolving picture. JAMA 2005; 293:233.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f8_39_8817=[""].join("\n");
var outline_f8_39_8817=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIGH-FIBER DIET OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS FIBER?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BENEFITS OF A HIGH-FIBER DIET",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HOW MUCH FIBER DO I NEED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           FIBER SIDE EFFECTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/31/39413\" title=\"figure 1\">",
"           Nutrition label fiber PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29661\" title=\"table 1\">",
"           Fiber in foods PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f8_39_8818="Patient information: Inflammatory breast cancer (The Basics)";
var content_f8_39_8818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/19/2357\">",
"         Patient information: Breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6115\">",
"         Patient information: Common breast problems (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/56/12167\">",
"         Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/56/6018\">",
"         Patient information: Common breast problems (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/47/5875\">",
"         Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Inflammatory breast cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/inflammatory-breast-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11051829\">",
"      <span class=\"h1\">",
"       What is inflammatory breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Inflammatory breast cancer (IBC) is a rare form of breast cancer. It makes the breast look red and swollen. The skin can also have pits or dimples. These can make the skin look like the skin on an orange. &nbsp;",
"     </p>",
"     <p>",
"      Breast cancer happens when normal cells in the breast change and grow out of control. In a person with IBC, this can happen very quickly.",
"     </p>",
"     <p>",
"      IBC is a serious form of breast cancer. It gets worse quickly. It can spread easily to other parts of the body. A person with IBC should get treatment right away. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11051844\">",
"      <span class=\"h1\">",
"       What are the symptoms of inflammatory breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of IBC are different from other forms of breast cancer. For example, it might NOT cause a lump in the breast.",
"     </p>",
"     <p>",
"      Symptoms of IBC include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Skin changes on 1 or both breasts. These can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Skin that feels warm or hot &nbsp;",
"       </li>",
"       <li>",
"        Color changes &ndash; Skin looks pink, red, or purple. &nbsp;",
"       </li>",
"       <li>",
"        Thicker skin",
"       </li>",
"       <li>",
"        Dimples or pits on the skin -- This can look like the skin on an orange.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Nipple changes on 1 or both breasts. These can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Flat nipple",
"       </li>",
"       <li>",
"        Nipple that turns red",
"       </li>",
"       <li>",
"        A crust or blister on the nipple",
"       </li>",
"       <li>",
"        Nipple that points in (if it pointed out before)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Painful, swollen breast",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11051859\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you have any of the symptoms above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11051874\">",
"      <span class=\"h1\">",
"       Is there a test for inflammatory breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will order a special kind of X-ray called a &ldquo;mammogram.&rdquo; This is a test for breast cancer. It is done on both breasts, even if just 1 breast has symptoms.",
"     </p>",
"     <p>",
"      The doctor or nurse will do an exam and learn about the symptoms. This can help find IBC. It can also show if another condition is causing the symptoms.",
"     </p>",
"     <p>",
"      If you might have IBC, you will probably have another test called a &ldquo;biopsy.&rdquo; During a biopsy, a doctor takes 1 or more small samples of tissue. These samples can be from:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The breast",
"       </li>",
"       <li>",
"        The skin on the breast",
"       </li>",
"       <li>",
"        The lymph nodes &ndash; These are small, bean-shaped organs that are part of the body&rsquo;s infection-fighting system.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have IBC, the doctor might order imaging tests to see if the cancer has spread. These imaging tests might be a CT, bone scan, or other imaging tests. Imaging tests create detailed pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11051889\">",
"      <span class=\"h1\">",
"       How is inflammatory breast cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with IBC have the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy&nbsp;&ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. If a person has IBC, doctors give these medicines before surgery or radiation therapy. The medicines can shrink the cancer.",
"       </li>",
"       <li>",
"        Mastectomy &ndash; Mastectomy is surgery to remove the whole breast. A &ldquo;radical mastectomy&rdquo; also removes other tissue, such as nearby muscle and lymph nodes. A person with IBC might have a radical mastectomy. This helps doctors take out as much cancer as possible. &nbsp;",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells. Most people with IBC have radiation after chemotherapy and surgery. But sometimes doctors do not think surgery will take out all the cancer. If that happens, they might do radiation instead of surgery.",
"       </li>",
"       <li>",
"        Hormone therapy&nbsp;&ndash; Some forms of breast cancer grow in response to hormones. The doctor might give you treatments to block hormones. Treatments can also stop your body from making certain hormones.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11051904\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you need to be checked as often as the doctor says. IBC often comes back after treatment. The doctor will check to see if it comes back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11051921\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       Patient information: Breast cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"       Patient information: Common breast problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=see_link\">",
"       Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=see_link\">",
"       Patient information: Common breast problems (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/39/8818?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83033 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8818=[""].join("\n");
var outline_f8_39_8818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11051829\">",
"      What is inflammatory breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11051844\">",
"      What are the symptoms of inflammatory breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11051859\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11051874\">",
"      Is there a test for inflammatory breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11051889\">",
"      How is inflammatory breast cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11051904\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11051921\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=related_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=related_link\">",
"      Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_39_8819="Esophageal varices PI";
var content_f8_39_8819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Esophageal varices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 537px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cirrhosis can cause the blood vessels around the esophagus to swell. This is called \"esophageal varices\". In severe cases, these blood vessels can burst and cause internal bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8819=[""].join("\n");
var outline_f8_39_8819=null;
var title_f8_39_8820="Dexrazoxane: Patient drug information";
var content_f8_39_8820=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dexrazoxane: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"     see \"Dexrazoxane: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/6/10342?source=see_link\">",
"     see \"Dexrazoxane: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Totect&reg;;",
"     </li>",
"     <li>",
"      Zinecard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zinecard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the side effects of doxorubicin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop skin problems from some drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701920",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dexrazoxane or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a heart function test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given with your cancer drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using ice on the problem skin, take the ice off 15 minutes before your shot.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11718 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8820=[""].join("\n");
var outline_f8_39_8820=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158534\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019176\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019178\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019177\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019182\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019183\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019185\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019180\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019187\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=related_link\">",
"      Dexrazoxane: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/6/10342?source=related_link\">",
"      Dexrazoxane: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_39_8821="Atrophic glossitis";
var content_f8_39_8821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrophic glossitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A smooth tongue that has lost its papillae and is often sore suggest a deficiency in riboflavin, niacin, folic acid, vitamin B12 or iron. This patient had vitamin B12 deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8821=[""].join("\n");
var outline_f8_39_8821=null;
var title_f8_39_8822="Pilomatricoma 1";
var content_f8_39_8822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pilomatricoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A firm blue-gray papule is present on the cheek of this 12-year-old girl.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8822=[""].join("\n");
var outline_f8_39_8822=null;
var title_f8_39_8823="Glimepiride: Drug information";
var content_f8_39_8823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glimepiride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/30/38372?source=see_link\">",
"    see \"Glimepiride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amaryl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amaryl&reg;;",
"     </li>",
"     <li>",
"      Apo-Glimepiride&reg;;",
"     </li>",
"     <li>",
"      Novo-Glimepiride;",
"     </li>",
"     <li>",
"      PMS-Glimepiride;",
"     </li>",
"     <li>",
"      ratio-Glimepiride;",
"     </li>",
"     <li>",
"      Sandoz-Glimepiride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral: Initial: 1-2 mg once daily, administered with breakfast or the first main meal; based on response, may increase dose by 1-2 mg every 1-2 weeks up to maximum of 8 mg daily.  If inadequate response to maximal dose, combination therapy with other agents (eg, metformin, insulin) may be considered. Combination therapy is individualized based on glycemic response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Conversion from therapy with long half-life agents:",
"     </i>",
"     Observe patient carefully for 1-2 weeks when converting from a longer half-life agent (eg, chlorpropamide) to glimepiride due to overlapping hypoglycemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes",
"     </b>",
"     : Oral:",
"     <i>",
"      Initial:",
"     </i>",
"     1 mg once daily; dose titration and maintenance dosing should be conservative to avoid hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F176243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Initial: 1 mg once daily; titrate carefully based on fasting blood glucose levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild-to-moderate impairment: Initial: 1 mg once daily; titrate carefully based on fasting blood glucose levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment: Use is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16027280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amaryl&reg;: 1 mg, 2 mg, 4 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer once daily with breakfast or first main meal of the day. Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise to lower blood glucose; may be used in combination with metformin or insulin in patients whose hyperglycemia cannot be controlled by diet and exercise in conjunction with a single oral hypoglycemic agent",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F176280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Glimepiride may be confused with glipiZIDE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amaryl&reg; may be confused with Altace&reg;, Amerge&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amarel [France], Amaryl [U.S., Canada, and multiple international markets] may be confused with Reminyl brand name for galantamine [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amaryl [U.S., Canada, and multiple international markets] may be confused with Almarl brand name for arotinolol [Japan]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Endocrine &amp; metabolic: Hypoglycemia (4% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2%), headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, anaphylaxis, angioedema, anorexia, aplastic anemia, cholestatic jaundice, constipation, diarrhea, disulfiram-like reaction, diuretic effect, edema, epigastric fullness, erythema, gastrointestinal pain, heartburn, hemolytic anemia, hepatic porphyria, hepatitis, hypoglycemia, hyponatremia, hypotension, leukopenia, liver failure, liver function tests abnormal, pancytopenia, photosensitivity, porphyria cutanea tarda, pruritus, rash (morbilliform or maculopapular), shock, SIADH, Stevens-Johnson syndrome, thrombocytopenia, urticaria, vasculitis (allergic), visual accommodation changes (early treatment), weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glimepiride, any component of the formulation, or sulfonamides; diabetic ketoacidosis (with or without coma)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Pregnancy; breast-feeding; severe renal or hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F176267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F176232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Caution with ethanol (may cause hypoglycemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Caution with chromium, garlic, gymnema (may cause hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies; therefore, glimepiride is classified as pregnancy category C. Severe hypoglycemia lasting 4-10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. The manufacturer recommends that patients be switched to insulin during pregnancy. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5650825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if glimepiride is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. Potentially, hypoglycemia may occur in a nursing infant exposed to a sulfonylurea via breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F176223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with breakfast or the first main meal of the day. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F176221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amaryl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $87.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $142.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $267.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Glimepiride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $40.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $65.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $122.83",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for signs and symptoms of hypoglycemia (fatigue, excessive hunger, profuse sweating, numbness of extremities), fasting blood glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F176212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F176224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acotril (PH);",
"     </li>",
"     <li>",
"      Aforglim (PH);",
"     </li>",
"     <li>",
"      Amadiab (ID);",
"     </li>",
"     <li>",
"      Amarel (FR);",
"     </li>",
"     <li>",
"      Amarine (TW);",
"     </li>",
"     <li>",
"      Amaryl (AR, AT, AU, BB, BF, BG, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, GT, GY, HK, HN, HR, ID, IE, IL, IN, IT, JM, KE, KP, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, PA, PE, PK, PL, PR, PT, PY, RU, SC, SD, SE, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Amarylle (BE);",
"     </li>",
"     <li>",
"      Amepirise (TW);",
"     </li>",
"     <li>",
"      Amorin (KP);",
"     </li>",
"     <li>",
"      Arya (PH);",
"     </li>",
"     <li>",
"      Aylide (AU);",
"     </li>",
"     <li>",
"      Azulix (PH);",
"     </li>",
"     <li>",
"      Diaglime (ID);",
"     </li>",
"     <li>",
"      Dialosa (GR, SG);",
"     </li>",
"     <li>",
"      Diamex (PH);",
"     </li>",
"     <li>",
"      Diapride (AU, HK, MY, SG);",
"     </li>",
"     <li>",
"      Dimirel (AU);",
"     </li>",
"     <li>",
"      Endial (AR);",
"     </li>",
"     <li>",
"      Euglex (KP);",
"     </li>",
"     <li>",
"      Euglim (IN);",
"     </li>",
"     <li>",
"      Getryl (PH);",
"     </li>",
"     <li>",
"      Glemaz (EC);",
"     </li>",
"     <li>",
"      Glenix (MY);",
"     </li>",
"     <li>",
"      Glimaccord (NZ);",
"     </li>",
"     <li>",
"      Glimaryl (HK, MY, TW);",
"     </li>",
"     <li>",
"      Glimep (KP);",
"     </li>",
"     <li>",
"      Glimepid (KP);",
"     </li>",
"     <li>",
"      Glimeryl (HK);",
"     </li>",
"     <li>",
"      Glimide (PE);",
"     </li>",
"     <li>",
"      Gludine (KP);",
"     </li>",
"     <li>",
"      Glupen (KP);",
"     </li>",
"     <li>",
"      Gluvas (ID);",
"     </li>",
"     <li>",
"      Hanmaryl (KP);",
"     </li>",
"     <li>",
"      Mapryl (ID);",
"     </li>",
"     <li>",
"      Metrix (ID);",
"     </li>",
"     <li>",
"      Miaryl (KP, MY);",
"     </li>",
"     <li>",
"      Norizec (PH);",
"     </li>",
"     <li>",
"      Paride (ID);",
"     </li>",
"     <li>",
"      Solosa (PH);",
"     </li>",
"     <li>",
"      Sulfast (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Blood glucose reductions: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 100%; delayed when given with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 8.8 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic oxidation via CYP2C9 to M1 metabolite (~33% activity of parent compound); further oxidative metabolism to inactive M2 metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60%, 80% to 90% as M1 and M2 metabolites); feces (40%, 70% as M1 and M2 metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alexander RW, &ldquo;Prolonged Hypoglycemia Following Acetohexamide Administration,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1966, 15(5):362-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/5936465/pubmed\" id=\"5936465\" target=\"_blank\">",
"        5936465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Study of the Effects of Hypoglycemia Agents on Vascular Complications in Patients With Adult-onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated With Tolbutamide. The University Group Diabetes Program,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1976, 25(12):1129-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/992232/pubmed\" id=\"992232\" target=\"_blank\">",
"        992232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cowen DL, Burtis B, and Youmans J, &ldquo;Prolonged Coma After Acetohexamide Ingestion,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1967, 201(2):141-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/6072340/pubmed\" id=\"6072340\" target=\"_blank\">",
"        6072340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):854-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/9742977/pubmed\" id=\"9742977\" target=\"_blank\">",
"        9742977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/9935017/pubmed\" id=\"9935017\" target=\"_blank\">",
"        9935017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klamann A, Sarfert P, Launhardt V, et al, &ldquo;Myocardial Infarction in Diabetic vs Nondiabetic Subjects. Survival and Infarct Size Following Therapy With Sulfonylureas (Glibenclamide),&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2000, 21(3):220-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/10639304/pubmed\" id=\"10639304\" target=\"_blank\">",
"        10639304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meinert CL, Knatterud GL, Prout TE, et al, &ldquo;A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset Diabetes. II. Mortality Results,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1970, 19:789-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/4926376/pubmed\" id=\"4926376\" target=\"_blank\">",
"        4926376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Keefe JH, Blackstone EH, Sergeant P, et al, &ldquo;The Optimal Mode of Coronary Revascularization for Diabetics. A Risk-Adjusted Long-Term Study Comparing Coronary Angioplasty and Coronary Bypass Surgery,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1998, 19(11):1696-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/9857923/pubmed\" id=\"9857923\" target=\"_blank\">",
"        9857923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8823/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8491 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8823=[""].join("\n");
var outline_f8_39_8823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176236\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176237\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176273\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176241\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176242\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176243\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16027280\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176211\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176197\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176216\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176215\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176280\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176271\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176219\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176201\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176267\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176206\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176232\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176207\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176222\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176247\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5650825\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176223\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176221\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176209\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176212\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176224\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176200\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176218\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/30/38372?source=related_link\">",
"      Glimepiride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_39_8824="Tuberculosis verrucosa cutis histopathology";
var content_f8_39_8824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Tuberculosis verrucosa cutis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This specimen from a lesion of tuberculosis verrucosa cutis demonstrates epidermal acanthosis, intraepidermal abscess formation, and a&nbsp;lichenoid&nbsp;lymphohistiocytic infiltrate in the dermis (A). A multinucleated giant cell is visible at higher magnification (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Research Institute for Tropical Medicine, Philippines.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8824=[""].join("\n");
var outline_f8_39_8824=null;
var title_f8_39_8825="Dabigatran: Drug information";
var content_f8_39_8825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dabigatran: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"    see \"Dabigatran: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F12705411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Dabigatran Etexilate (Pradaxa&reg;) Contraindicated in Patients with Mechanical Prosthetic Heart Valves",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) and Health Canada have issued Drug Safety Communication warnings against the use of dabigatran etexilate in patients with mechanical prosthetic heart valves. The RE-ALIGN clinical trial conducted in Europe was terminated early after discovering that mechanical heart valve patients taking dabigatran were more likely to experience stroke, myocardial infarction, and mechanical valve thrombosis compared to patients taking adjusted dose warfarin. Major bleeding (eg, pericardial effusion) after valve surgery was also increased. Therefore, the FDA and Health Canada are requiring a new contraindication for dabigatran manufacturer&rsquo;s labeling against use in patients with mechanical heart valves. Healthcare professionals should immediately transition any patient receiving dabigatran with a mechanical heart valve to another anticoagulant (eg, warfarin). Of note, dabigatran use in patients with bioprosthetic valves (valves made of natural biological tissue) has not been evaluated and cannot be recommended. Patients currently taking dabigatran who have any type of prosthetic heart valve (mechanical or bioprosthetic) should continue to take dabigatran, but immediately contact their health care professional for guidance.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at:",
"      </p>",
"      <p style=\"text-indent:0em;\">",
"       U.S.:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm332912.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm332912.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:0em;\">",
"       Canada: file://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/pradaxa_hpc-cps-eng.php",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Reports Safety Review Findings Regarding Postmarketing Serious Bleeding Adverse Events with Dabigatran Etexilate (Pradaxa&reg;): Update",
"     </span>",
"     <span class=\"collapsible-date\">",
"      November 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) performed a safety review in response to postmarketing reports of serious bleeding associated with dabigatran use. In preapproval studies versus warfarin, dabigatran had comparable rates of serious bleeding. As part of the Mini-Sentinel pilot of the Sentinel Initiative, the FDA did a retrospective assessment of actual gastrointestinal and intracranial bleeding rates associated with new use of both dabigatran and warfarin in atrial fibrillation patients. The comparison used health insurance claims and administrative data from patients who met the criteria. Gastrointestinal and intracranial bleeding rates associated with initiation of dabigatran do not appear to be higher than the bleeding events seen with new use of warfarin; these results are consistent with the dabigatran approval trial (RE-LY).",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA&rsquo;s recommendations regarding dabigatran remain unchanged. When prescribing dabigatran, the FDA recommends following product label dosing, especially in patients with renal impairment. Patients with atrial fibrillation are advised not to stop taking dabigatran without talking to their health care providers, as stopping use of anticoagulants may increase the risk of stroke.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found on the FDA&rsquo;s website at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10968125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pradaxa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6209555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pradaxa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6209558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant, Thrombin Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6211475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):",
"     </b>",
"     Oral: 150 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     The American Heart Association/American Stroke Association recommends dabigatran as a reasonable alternative to warfarin in patients who have &ge;1 additional risk factor for stroke and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute (Furie, 2012). The American College of Chest Physicians (ACCP) suggests dabigatran over warfarin for primary and secondary prevention of nonvalvular atrial fibrillation-induced cardioembolic stroke or TIA.  For secondary prevention, initiate therapy within 1-2 weeks after stroke onset or earlier in patients at low bleeding risk (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Conversion from a parenteral anticoagulant:",
"     </i>",
"     Initiate dabigatran &le;2 hours prior to the time of the next scheduled dose of the parenteral anticoagulant (eg, enoxaparin) or at the time of discontinuation for  a continuously administered parenteral drug (eg, I.V. heparin); discontinue parenteral anticoagulant at the time of dabigatran initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Conversion to a parenteral anticoagulant:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     U.S. labeling: Wait 12 hours (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute) or 24 hours (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) after the last dose of dabigatran before initiating a parenteral anticoagulant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Canadian labeling: Wait 12 hours after the last dose of dabigatran before initiating a parenteral anticoagulant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Conversion from warfarin:",
"     </i>",
"     Discontinue warfarin and initiate dabigatran when INR &lt;2.0",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Conversion to warfarin:",
"     </i>",
"     Start time must be adjusted based on Cl",
"     <sub>",
"      cr",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Initiate warfarin 3 days before discontinuation of dabigatran",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-50 mL/minute: Initiate warfarin 2 days before discontinuation of dabigatran",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: Initiate warfarin 1 day before discontinuation of dabigatran (dabigatran use is contraindicated in Canadian labeling when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: No recommendations provided in the U.S. manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Since dabigatran contributes to INR elevation, warfarin&rsquo;s effect on the INR will be better reflected only after dabigatran has been stopped for &ge;2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Postoperative  thromboprophylaxis (Canadian labeling):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Knee replacement:",
"     </i>",
"     Initial: 110 mg given 1-4 hours after completion of surgery and establishment of hemostasis",
"     <b>",
"      OR",
"     </b>",
"     220 mg as 1 dose in postoperative patients in whom therapy is not initiated on day of surgery regardless of reason; maintenance: 220 mg once daily (total duration of therapy: 10 days; ACCP recommendation [Guyatt, 2012]: Minimum of 10-14 days; extended duration of up to 35 days suggested)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Hip replacement:",
"     </i>",
"     Initial: 110 mg given 1-4 hours after completion of surgery and establishment of hemostasis",
"     <b>",
"      OR",
"     </b>",
"     220 mg as 1 dose in postoperative patients in whom therapy is not initiated on day of surgery regardless of reason; maintenance: 220 mg once daily (total duration of therapy: 28-35 days; ACCP recommendation [Guyatt, 2012]: Minimum of 10-14 days; extended duration of up to 35 days suggested)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Conversion information (Canadian labeling):",
"     </i>",
"     When transitioning from parenteral anticoagulation therapy, initiate oral dabigatran therapy &le;2 hours prior to the time of next regularly scheduled dose of intermittent parenteral anticoagulant or at the time of discontinuation for continuously administered parenteral anticoagulation therapy. When transitioning from dabigatran to I.V. anticoagulation therapy following hip- or knee-replacement surgery, allow 24 hours after the last dabigatran dose before initiating I.V. anticoagulation therapy. When transitioning from warfarin, discontinue warfarin and initiate dabigatran when INR &lt;2.0.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      <i>",
"       Dosing adjustment with concomitant medications:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling: Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Dronedarone or ketoconazole (oral) with Cl",
"      <sub>",
"       cr",
"      </sub>",
"      30-50 mL/minute:",
"     </i>",
"     Consider dabigatran dose reduction to 75 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Any P-glycoprotein inhibitor (including dronedarone and oral ketoconazole) with Cl",
"      <sub>",
"       cr",
"      </sub>",
"      &lt;30 mL/minute:",
"     </i>",
"     Avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling: Postoperative thromboprophylaxis:",
"     <i>",
"      Strong P-gp inhibitors (eg, amiodarone, quinidine, verapamil):",
"     </i>",
"     Use caution and reduce dabigatran to 150 mg once daily. In patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute and receiving verapamil, consider dabigatran dose reduction to 75 mg once daily. Use with the strong P-gp inhibitor ketoconazole (oral) is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6211476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients &gt;65 years: Refer to adult dosing. No dosage adjustment required unless renal impairment exists; however, increased risk of bleeding has been observed, particularly in elderly patients with low body weight and/or concomitant renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients &ge;80 years:",
"     <b>",
"      Use with extreme caution or consider other treatment options;",
"     </b>",
"     no dosage adjustment provided in manufacturer&rsquo;s labeling; however, numerous cases of hemorrhage, including hemorrhagic stroke, have been reported postmarketing, particularly in this age group of octogenarians. Due to a lack of available dosing options available in the U.S., consider avoiding use of dabigatran in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients &lt;80 years: 150 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer labeling suggests that a dose reduction to 110 mg twice daily may be considered in patients &gt;75 years with at least one other risk factor for bleeding (eg, moderate renal impairment [Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute], concomitant treatment with strong P-gp inhibitors, or previous GI bleed); however, efficacy in stroke prevention may be lessened with this dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients &ge;80 years: 110 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postoperative thromboprophylaxis (Canadian labeling):",
"     </b>",
"     Oral: Patients &gt;75 years: Use with caution; consider a dose of 150 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6211477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Clinical trial evaluating safety and efficacy utilized the Cockcroft-Gault formula with the use of actual body weight (data on file; Boehringer Ingelheim Pharmaceuticals Inc, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary. Use with caution in mild renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute) due to risk for increased dabigatran exposure (area under the curve may be increased 1.5 times higher than normal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: No dosage adjustment necessary",
"     <b>",
"      unless",
"     </b>",
"     patient receiving concomitant dronedarone or oral ketoconazole, then consider reducing dabigatran to 75 mg twice daily. Use with caution in moderate renal impairment due to risk for increased dabigatran exposure (area under the curve may be increased 3 times higher than normal), particularly if patient is also of advanced age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: 75 mg twice daily",
"     <b>",
"      unless",
"     </b>",
"     patient receiving concomitant P-gp inhibitor (including dronedarone or oral ketoconazole), then avoid concurrent use.",
"     <b>",
"      Note:",
"     </b>",
"     Patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute were excluded from the RE-LY trial (Connolly, 2009). Dose based on pharmacokinetic data; safety and efficacy has not been established. Per the American College of Chest Physicians, dabigatran is considered contraindicated in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute) (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Use not recommended (has not been studied). Per the American College of Chest Physicians, dabigatran is considered contraindicated in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute) (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     ESRD requiring hemodialysis: Use not recommended (has not been studied);",
"     <b>",
"      Note:",
"     </b>",
"     Hemodialysis removes ~60% over 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: No dosage adjustment necessary",
"     <b>",
"      Note:",
"     </b>",
"     Patients with moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute) are at an increased risk for bleeding; routine assessment of renal status is recommended; use recommended unadjusted dosage of 150 mg twice daily with caution in these patients. A dosage reduction to 110 mg twice daily may be considered for patients &ge;75 years and/or those with other bleeding risk factors; however, efficacy in stroke prevention may be lessened with this dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Postoperative thromboprophylaxis:",
"     </b>",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Initial: 75 mg given 1-4 hours after completion of surgery and establishment of hemostasis; Maintenance: 150 mg once daily",
"     <b>",
"      unless",
"     </b>",
"     patient receiving concomitant verapamil, then consider reducing dabigatran to 75 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6211478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-top:0em;\">",
"     U.S. labeling: No dosage adjustment provided in manufacturer&rsquo;s labeling; consistent changes in exposure or pharmacodynamics were not observed in a study of patients with moderate impairment.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-top:0em;\">",
"     Canadian labeling: Use is not recommended if hepatic enzymes &gt;3 x ULN.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10924947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pradaxa&reg;: 75 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10925866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Pradax&trade;: 75 mg, 110 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10925306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231720.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231720.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6211505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not break, chew, or open capsules, as this will lead to 75% increase in absorption and potentially serious adverse reactions. Administer with water. May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6209560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     2011 ACCF/AHA/HRS atrial fibrillation guidelines: Not recommended for patients with coexisting prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute), or advanced liver disease (impaired baseline clotting function)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional uses (not in U.S. labeling): Postoperative thromboprophylaxis in patients who have undergone total hip or knee replacement procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13273235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pradaxa&reg; may be confused with Plavix&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pradax&trade; (Canada) may be confused with Plavix&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - weak).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6209613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions listed below are reflective of both the U.S. and Canadian product information.",
"     <b>",
"      Important:",
"     </b>",
"     No specific antidote exists for dabigatran reversal. Therapy for severe hemorrhage may include transfusions of fresh frozen plasma, packed red blood cells, or surgical intervention when appropriate (Wann, 2011). The use of a prothrombin complex concentrate (PCC) (Cofact&reg;, not available in the U.S.) has been shown to be",
"     <b>",
"      ineffective",
"     </b>",
"     for dabigatran reversal (Eerenberg, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (11%; includes abdominal discomfort/pain, epigastric discomfort)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Bleeding (8% to 33%; major: &le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: GI hemorrhage (&le;6%), gastritis-like symptoms (eg, GERD, esophagitis, erosive gastritis, GI ulcer)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (1% to 4%), hematoma (1% to 2%), hemoglobin decreased (1% to 2%), hemorrhage (postprocedural or wound: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (&ge;3 x ULN: 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Hematuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Wound secretion (5%), postprocedural discharge (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic edema, anaphylactic shock, anaphylaxis, AST increased, bloody discharge, ecchymosis, epistaxis, hemarthrosis, hematocrit decreased, hemorrhage (catheter site, hemorrhoidal, incision site, rectal), hepatic function abnormal, occult blood positive, pruritus, rash, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6209605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious hypersensitivity (eg, anaphylaxis) to dabigatran or any component of the formulation; active pathological bleeding; patients with mechanical prosthetic heart valve(s)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); bleeding diathesis or patients with spontaneous or pharmacological hemostatic impairment; lesions at risk of clinically significant bleeding (eg, hemorrhagic or ischemic cerebral infarction) within previous 6 months; concomitant therapy with oral ketoconazole; concomitant use with other anticoagulants including unfractionated heparin (except when used to maintain central venous or arterial catheter patency), low molecular weight heparins, heparin derivatives (eg, fondaparinux), anti-thrombin agents (eg, bivalirudin), and oral anticoagulants (eg, warfarin, rivaroxaban, apixaban) except during transitioning of therapy from or to dabigatran",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6209606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding: The most common complication is bleeding, sometimes fatal bleeding. Risk factors for bleeding include concurrent use of drugs that increase the risk of bleeding (eg, antiplatelet agents, heparin), renal impairment, and elderly patients (especially if low body weight). Monitor for signs and symptoms of bleeding; discontinue in patients with active pathological bleeding.",
"     <b>",
"      Important:",
"     </b>",
"     No specific antidote exists for dabigatran reversal; protamine and vitamin K do not reverse or impact anticoagulant effects of dabigatran. Dabigatran is dialyzable (~60% removed over 2-3 hours); however, supporting data are limited for utilizing this method. Therapy for severe hemorrhage may include transfusions of fresh frozen plasma, packed red blood cells, or surgical intervention when appropriate (Wann, 2011). The use of a PCC (Cofact&reg;, not available in the U.S.) has been shown to be",
"     <b>",
"      ineffective",
"     </b>",
"     for dabigatran reversal (Eerenberg, 2011); however, the manufacturer does suggest that activated PCC (eg, FEIBA NF), recombinant factor VIIa, or concentrates of factors II, IX, or X may be considered, although their use has not been evaluated in clinical trials. Platelet concentrates should be considered when thrombocytopenia is present or long-acting antiplatelet drugs have been used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use in patients with moderate hepatic impairment (Child-Pugh class B) demonstrated large inter-subject variability; however, no consistent change in exposure or pharmacodynamics was seen. Use in patients with advanced liver disease (impaired baseline clotting function) is not recommended (Wann, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Evaluate renal function prior to and during therapy, particularly if used in patients with any degree of pre-existing renal impairment or in any condition that may result in a decline in renal function (eg, hypovolemia, dehydration, concomitant use of medications with a potential to affect renal function); dabigatran concentrations may increase in any degree of renal impairment and increase the risk of bleeding. In moderate impairment, serum concentrations may increase 3 times higher than normal compared to concentrations in patients with normal renal function. However, U.S. labeling only requires dosage reduction in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute) and recommends avoiding use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute due to insufficient evidence. Per the American College of Chest Physicians, dabigatran is considered contraindicated in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute) (Guyatt, 2012). The Canadian labeling also contraindicates use in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) and recommends indication-specific dose reductions in patients with moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute). Discontinue therapy in any patient who develops acute renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Valvular heart disease: Use is not recommended in patients with bioprosthetic heart valves; use is contraindicated in patients with mechanical prosthetic heart valves. In addition to several case reports (Chu, 2012; Price, 2012; Stewart, 2012), one clinical trial reported significantly more thromboembolic events (valve thrombosis, stroke, TIA, and MI) and an excess of major bleeding (predominantly postoperative pericardial effusions requiring intervention for hemodynamic compromise) in patients with mechanical prosthetic heart valves receiving dabigatran compared to those receiving adjusted-dose warfarin. Use in patients with atrial fibrillation in the setting of other forms of valvular heart disease, including presence of a bioprosthetic heart valve is not recommended (has not been evaluated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antithrombotic agents: Due to an increased risk of bleeding, avoid use, if possible, with other direct thrombin inhibitors (eg, bivalirudin), unfractionated heparin or heparin derivatives, low molecular weight heparins (eg, enoxaparin), fondaparinux, thienopyridines (eg, clopidogrel), GPIIb/IIIa antagonists (eg, eptifibatide), aspirin, coumarin derivatives, sulfinpyrazone, and ticagrelor. NSAIDs should be used cautiously. Appropriate doses of unfractionated heparin may be used to maintain catheter patency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; P-glycoprotein (P-gp) inducers/inhibitors: The concomitant use of P-gp inducers (eg, rifampin) may reduce dabigatran bioavailability and should be avoided. Recommendations regarding concomitant use with P-gp inhibitors (eg, ketoconazole, dronedarone) may vary (see Drug Interactions). Concomitant use with any P-gp inhibitor should be avoided for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly:",
"     <b>",
"      Use with extreme caution or consider other treatment options.",
"     </b>",
"     No dosage adjustment is recommended in the U.S. labeling based on age alone (unless renal impairment coexists); however, numerous case reports of hemorrhage (including hemorrhagic stroke) have been reported in elderly patients (median age: 80 years), with a quarter of these reports occurring in patients &ge;84 years of age. Some reports have resulted in fatality, particularly in those with low body weight and mild-to-moderate renal impairment; the risk is expected to be higher in patients receiving other interacting drugs (eg, amiodarone) (Legrand, 2011). The RE-LY trial, although not powered to assess safety in the elderly, employed 110 mg and 150 mg twice daily regimens. The 110 mg twice daily regimen was not approved for use in the United States. The Canadian labeling recommends a dose reduction for patients &ge;80 years of age with atrial fibrillation and further suggests that dose reductions be considered in patients &gt;75 years of age receiving therapy for atrial fibrillation or postoperative thromboprophylaxis. In addition, due to the frequency of renal impairment in older adults, the Canadian labeling recommends monitoring renal function at a minimum of once per year in any patient  &gt;75 years of age; use of dabigatran is contraindicated in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute. Per the Beers Criteria, there is a greater risk of bleeding in older adults aged &ge;75 years (exceeds warfarin bleeding risk) and therapy should be used with caution in patients &ge;75 years of age or in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Invasive or surgical procedures: If possible, discontinue dabigatran 1-2 days (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute) or 3-5 days (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute) before invasive or surgical procedures due to the risk of bleeding; consider longer times for patients undergoing major surgery, spinal puncture, or insertion of a spinal or epidural catheter or port. If surgery cannot be delayed, the risk of bleeding is elevated; weigh risk of bleeding with urgency of procedure. Bleeding risk can be assessed by the ecarin clotting time (ECT) if available; if ECT is not available, use of aPTT may provide an approximation of dabigatran&rsquo;s anticoagulant activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Discontinuation: When temporarily discontinuing anticoagulants, including dabigatran, for active bleeding, elective surgery, or invasive procedures, the risk of stroke may increase (dependent on amount of elapsed time); lapses in therapy should be minimized and reinitiation should begin as soon as possible.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6209617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel. Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Dabigatran Etexilate. Management: Canadian (but not U.S.) dabigatran prescribing information recommends limiting dabigatran dose for VTE prevention following hip/knee replacement to 150 mg/day.  No dose adjustment is recommended for dabigatran in atrial fibrillation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Dabigatran Etexilate. Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Dabigatran Etexilate may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May decrease the serum concentration of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Dabigatran Etexilate. Management: Increase monitoring for bleeding; dabigatran etexilate dose reduction may be necessary in moderate renal dysfunction; avoid this combination in severe renal dysfunction. Canadian labeling recommends avoiding this combination regardless of renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Dabigatran Etexilate. Management: Increase monitoring of any patient using this combination; dabigatran dose reduction may be needed in patients with moderate renal dysfunction; avoid the combination with severe renal dysfunction.  This combination is contraindicated in Canadian labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Dabigatran Etexilate. Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dabigatran Etexilate. Management: Canadian (but not U.S.) prescribing information recommends dosing dabigatran 2 hours prior to quinidine, and limiting dabigatran VTE prevention dose post hip/knee replacement to 150 mg/day in patients receiving quinidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfinpyrazone [Off Market]: May enhance the anticoagulant effect of Dabigatran Etexilate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Dabigatran Etexilate. Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. Management: Consider giving dabigatran 2 hrs before oral verapamil; other dose reductions may be needed. Specific recommendations vary by US vs Canadian labeling, renal function, and indication for dabigatran.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6209725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Food has no affect on the bioavailability of dabigatran, but delays the time to peak plasma concentrations by 2 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may decrease levels/effects of dabigatran (concomitant use is not recommended). Concomitant use of dabigatran with herbs possessing anticoagulant/antiplatelet properties may increase the risk for bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10924365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6209562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Data are insufficient to evaluate the safety of direct thrombin inhibitors during pregnancy; use of oral agents during pregnancy should be avoided (Guyatt, 2012). Consider the risks of bleeding and stroke if used during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6209604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13940482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dabigatran etexilate is not recommended for use in breast-feeding women; use of alternative anticoagulants is preferred.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6209726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Pradaxa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (60): $300.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $300.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6211507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine monitoring of coagulation tests not required. However, the measurement of activated partial thromboplastin time (aPTT) (values &gt;2.5 x control may indicate overanticoagulation), ecarin clotting test (ECT) if available, or thrombin time (TT; most sensitive) may be useful to determine presence of dabigatran and level of coagulopathy; CBC with differential; renal function (prior to initiation and periodically as clinically indicated [ie, situations associated with a decline in renal function]);",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling specifically recommends renal function be routinely assessed at least once per year in elderly patients (&gt;75 years of age) or patients with moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F12865073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     At therapeutic dabigatran doses, aPTT, ECT (ecarin clotting time), and TT (thrombin time) are prolonged. A median peak aPTT of ~2 x control and a median trough aPTT of 1.5 x control were observed in subjects taking dabigatran 150 mg twice daily in the RE-LY trial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     A therapeutic range has not been established for aPTT or for other tests of anticoagulant activity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pradaxa (AR, AT, AU, BE, CN, CO, CZ, DE, DK, EC, EE, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SV, TH, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6211503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prodrug lacking anticoagulant activity that is converted",
"     <i>",
"      in vivo",
"     </i>",
"     to the active dabigatran, a specific, reversible, direct thrombin inhibitor that inhibits both free and fibrin-bound thrombin. Inhibits coagulation by preventing thrombin-mediated effects, including cleavage of fibrinogen to fibrin monomers, activation of factors V, VIII, XI, and XIII, and inhibition of thrombin-induced platelet aggregation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6211464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid; initially slow postoperatively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 50-70 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; dabigatran etexilate is rapidly and completely hydrolyzed to dabigatran (active form) by plasma and hepatic esterases; dabigatran undergoes hepatic glucuronidation to active acylglucuronide isomers (similar activity to parent compound; accounts for &lt;10% of total dabigatran in plasma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 3% to 7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 12-17 hours; Elderly: 14-17 hours; Mild-to-moderate renal impairment: 15-18 hours; Severe renal impairment: 28 hours (Stangier, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Dabigatran: 1 hour; delayed 2 hours by food (no effect on bioavailability)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (80%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alban S, &ldquo;Pharmacological Strategies for Inhibition of Thrombin Activity,&rdquo;",
"      <i>",
"       Curr Pharm Des",
"      </i>",
"      , 2008, 14(12):1152-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/18473863/pubmed\" id=\"18473863\" target=\"_blank\">",
"        18473863",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blech S, Ebner T, Ludwig-Schwellinger E, et al, &ldquo;The Metabolism and Disposition of The Oral Direct Thrombin Inhibitor, Dabigatran, in Humans,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2008, 36(2):386-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/18006647/pubmed\" id=\"18006647\" target=\"_blank\">",
"        18006647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chu JW, Chen VH, and Bunton R, \"Thrombosis of a Mechanical Heart Valve Despite Dabigatran,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 157(4):304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/22910954/pubmed\" id=\"22910954\" target=\"_blank\">",
"        22910954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Connolly SJ, Ezekowitz MD, Yusuf S, et al, &ldquo;Dabigatran Versus Warfarin in Patients With Atrial Fibrillation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(12):1139-51",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/19717844/pubmed\" id=\"19717844\" target=\"_blank\">",
"        19717844",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al, &ldquo;Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(14):1573-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/21900088/pubmed\" id=\"21900088\" target=\"_blank\">",
"        21900088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eikelboom JW, Wallentin L, Connolly SJ, et al, &ldquo;Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2363-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/21576658/pubmed\" id=\"21576658\" target=\"_blank\">",
"        21576658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ezekowitz MD, Reilly PA, Nehmiz G, et al, &ldquo;Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study),&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2007, 100(9):1419-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/17950801/pubmed\" id=\"17950801\" target=\"_blank\">",
"        17950801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson BI, Dahl OE, Kurth AA, et al, &ldquo;Oral Dabigatran Etexilate Versus Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolism after Total Knee Replacement: The RE-MODEL Randomized Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2007, 5(11):2178-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/17764540/pubmed\" id=\"17764540\" target=\"_blank\">",
"        17764540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson BI, Dahl OE, Rosencher N, et al, &ldquo;Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism after Total Hip Replacement: A Randomised, Double-Blind, Non-Inferiority Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9591):949-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/17869635/pubmed\" id=\"17869635\" target=\"_blank\">",
"        17869635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furie KL, Goldstein LB, Albers GW, et al, &ldquo;Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals from the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2012, 43(12):3442-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/22858728/pubmed\" id=\"22858728\" target=\"_blank\">",
"        22858728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Legrand M, Mateo J, Aribaud A, et al, &ldquo;The Use of Dabigatran in Elderly Patients,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2011, 171(14):1285-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/21788545/pubmed\" id=\"21788545\" target=\"_blank\">",
"        21788545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marlu R, Hodaj E, Paris A, et al, &ldquo;Effect of Non-Specific Reversal Agents on Anticoagulant Activity of Dabigatran and Rivaroxaban,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2012, 108(2):217-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/22627883/pubmed\" id=\"22627883\" target=\"_blank\">",
"        22627883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nutescu EA, Shapiro NL, and Chevalier A, &ldquo;New Anticoagulant Agents: Direct Thrombin Inhibitors,&rdquo;",
"      <i>",
"       Cardiol Clin",
"      </i>",
"      , 2008, 26(2): 169-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/18406993/pubmed\" id=\"18406993\" target=\"_blank\">",
"        18406993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Price J, Hynes M, Labinaz M, et al, \"Mechanical Valve Thrombosis With Dabigatran,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2012, 60(17):1710-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/23021328/pubmed\" id=\"23021328\" target=\"_blank\">",
"        23021328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stangier J, Eriksson BI, Dahl OE, et al, &ldquo;Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(5): 555-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/15831779/pubmed\" id=\"15831779\" target=\"_blank\">",
"        15831779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stangier J, Rathgen K, St&auml;hle H, et al, &ldquo;Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2010, 49(4):259-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/20214409/pubmed\" id=\"20214409\" target=\"_blank\">",
"        20214409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stewart RA, Astell H, Young L, et al, \"Thrombosis on a Mechanical Aortic Valve Whilst Anti-Coagulated With Dabigatran,\"",
"      <i>",
"       Heart Lung Circ",
"      </i>",
"      , 2012, 21(1):53-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/21937274/pubmed\" id=\"21937274\" target=\"_blank\">",
"        21937274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Ryn J, Stangier J, Haertter S, et al, &ldquo;Dabigatran Etexilate &ndash; A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2010, 103(6):1116-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/20352166/pubmed\" id=\"20352166\" target=\"_blank\">",
"        20352166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallentin L, Yusuf S, Ezekowitz MD, et al, &ldquo;Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9745):975-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/20801496/pubmed\" id=\"20801496\" target=\"_blank\">",
"        20801496",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, Ellenbogen KA, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(10):1144-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/21321155/pubmed\" id=\"21321155\" target=\"_blank\">",
"        21321155",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/39/8825/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8926 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8825=[""].join("\n");
var outline_f8_39_8825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12705411\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10968125\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209555\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209558\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6211475\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6211476\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6211477\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6211478\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10924947\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10925866\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10925306\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6211505\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209560\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273235\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209613\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209605\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209606\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299117\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209617\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209725\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10924365\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209562\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209604\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13940482\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209726\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321837\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6211507\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12865073\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875351\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6211503\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6211464\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8926|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=related_link\">",
"      Dabigatran: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_39_8826="Hematopoietic cell transplantation in myelodysplastic syndromes";
var content_f8_39_8826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic cell transplantation in myelodysplastic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/39/8826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/39/8826/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/39/8826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/39/8826/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/39/8826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/39/8826/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/39/8826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by chronic cytopenias with abnormal cellular maturation. Concomitant risks are infection, bleeding, anemia, and an increased risk of progression to acute leukemia, which is often refractory to standard treatments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no agreed upon standard treatment approach for patients with symptomatic MDS and patients should be encouraged to enroll in clinical trials whenever available. Our treatment approach incorporates knowledge of the patient&rsquo;s performance status, the International Prognostic Scoring System (IPSS) (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and revised IPSS (IPSS-R) (",
"    <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"     table 2",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) MDS risk categories, and other disease characteristics (ie, cytopenias present, serum erythropoietin level) to help guide management decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H515265#H515265\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Selection of initial treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allogeneic hematopoietic cell transplantation (HCT) is a treatment option for patients with intermediate-2, high, or very high risk MDS. A choice among treatment options in these populations is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=see_link&amp;anchor=H48546540#H48546540\">",
"     \"Treatment of high or very high risk myelodysplastic syndromes\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of MDS with HCT will be reviewed here. The clinical manifestations, diagnosis, prognosis, and treatment of this disorder with other therapies and the role of hematopoietic cell transplantation in children with MDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=see_link\">",
"     \"Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link\">",
"     \"Overview of the treatment of myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ALLOGENEIC HCT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15218057\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic HCT in MDS is limited by donor availability and the advanced age of most patients with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/1\">",
"     1",
"    </a>",
"    ]. In the past, patients over the age of 50 years were felt to be too old to undergo this aggressive treatment, due to transplant-related complications. With improvements in technique and supportive care, a number of groups have extended the upper age limit for myeloablative allogeneic HCT (allo-HCT) to 60 years or more using chemotherapy-based preparative regimens. However, since approximately 75 percent of patients with MDS are more than 60 years of age at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/2\">",
"     2",
"    </a>",
"    ], myeloablative allogeneic and syngeneic HCT can only be offered to a subset of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-myeloablative allogeneic HCT has brought new hope for patients not eligible for myeloablative allo-HCT either because they are too old or have other serious medical conditions. Results of these studies are ongoing (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Nonmyeloablative or reduced intensity regimens'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Despite this limitation, the European Group for Blood and Marrow Transplantation (EBMT) has transplanted over 1300 patients with MDS between 1983 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/4\">",
"     4",
"    </a>",
"    ]. This total includes patients receiving allo-HCT from fully-matched siblings or voluntary donors, mismatched related donors, and autologous transplants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Matched sibling allo-HCT (885 patients) &mdash; Estimated rates of disease-free survival, nonrelapse mortality, and relapse at three years were 36, 37, and 36 percent, respectively.",
"     </li>",
"     <li>",
"      Matched unrelated allo-HCT (198 patients) &mdash; Estimated rates of disease-free survival, nonrelapse mortality, and relapse at three years were 25, 58, and 41 percent, respectively.",
"     </li>",
"     <li>",
"      Mismatched related allo-HCT (91 patients) &mdash; Estimated rates of disease-free survival, nonrelapse mortality, and relapse at three years were 28, 66, and 18 percent, respectively.",
"     </li>",
"     <li>",
"      Autologous HCT in first complete remission (126 patients) &mdash; Estimated rates of disease-free survival, nonrelapse mortality, and relapse at three years were 33, 25, and 55 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Seattle group has described the outcome after allo-HCT in 93 patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. All patients had either severe neutropenia, thrombocytopenia, or greater than 5 percent bone marrow blasts. Patients were prepared with either total body irradiation (TBI) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (CY)",
"    <span class=\"nowrap\">",
"     (TBI/CY;",
"    </span>",
"    88 patients) or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"      busulfan",
"     </a>",
"     /cyclophosphamide",
"    </span>",
"    <span class=\"nowrap\">",
"     (BU/CY;",
"    </span>",
"    five patients). Sixty-five patients received grafts from HLA-matched sibling donors, whereas 28 patients received either marrow grafts from other family members or unrelated donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With a follow-up of four years, 41 percent of patients were alive and free of disease. Twenty-eight percent had relapsed and 43 percent died of transplant-related complications. As expected, those patients who had the best overall result were younger (&lt;40 years) and were transplanted with less than 5 percent bone marrow blasts.",
"   </p>",
"   <p>",
"    A 1998 update of the Seattle experience included 251 patients with MDS (median age of 38 years), stratified according to their IPSS risk score (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/7\">",
"     7",
"    </a>",
"    ]. Five-year disease-free survival was 60, 36, and 28 percent for patients in the low and intermediate-1, intermediate-2, and high risk groups, respectively. The authors concluded that allo-HCT may be recommended for patients with intermediate-1, intermediate-2, and high risk MDS, but not for patients with low risk disease.",
"   </p>",
"   <p>",
"    The use of a preparative regimen combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    with fractionated TBI resulted in similar outcomes, with an overall estimated survival of 26 percent at three years, and at 100 days a non-relapse mortality of 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/8\">",
"     8",
"    </a>",
"    ]. Therefore, other strategies, especially when utilizing unrelated donors, are needed.",
"   </p>",
"   <p>",
"    Other groups have reported similar results using TBI-based regimens, which were primarily combined with CY or",
"    <span class=\"nowrap\">",
"     BU/CY",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. The largest experience comes from the European Blood and Marrow Transplantation Group (EBMT), which analyzed 131 patients with MDS who underwent allo-HCT from HLA-matched sibling donors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/9\">",
"     9",
"    </a>",
"    ]. Fifty patients (38 percent) died of transplant related complications and relapse occurred in 28 (39 percent actuarial risk at five years).",
"   </p>",
"   <p>",
"    Patients with lesser degrees of MDS fared better, with five-year overall survival of 57, 42, 24, and 28 percent for patients with",
"    <span class=\"nowrap\">",
"     RA/RARS,",
"    </span>",
"    RAEB, RAEB-T, and secondary acute leukemia, respectively. The same variables found by the Seattle group were predictive of improved outcome: younger age (especially &lt;40), shorter disease duration, and absence of excess BM blasts, as well as a platelet count",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL",
"    </span>",
"    at the time of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/15\">",
"     15",
"    </a>",
"    ]. An update of the EBMT experience with 885 patients indicated three-year disease-free survivals of 45, 37, and 31 percent for patients transplanted at &lt;20, 20 to 40, and &gt;40 years of age, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    to",
"    <span class=\"nowrap\">",
"     TBI/Cy",
"    </span>",
"    has been explored in a small cohort of 18 patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/16\">",
"     16",
"    </a>",
"    ]. The findings of two-year probabilities of survival of 75 and 57 percent for low and high risk patients, respectively is encouraging, but requires validation in larger trials.",
"   </p>",
"   <p>",
"    Non-TBI based regimens have also been explored. In one report, 109 patients with MDS (age range: 6 to 66 years) were treated with a less toxic conditioning regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    targeted to predetermined plasma levels, followed by related or unrelated donor allo-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Non-relapse mortality at 100 days for HLA-identical sibling, matched unrelated, or HLA-nonidentical transplants was 12, 13, and 36 percent, respectively, with three-year relapse-free survivals of 56 to 59 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Matched unrelated donor allo-HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of matched unrelated donors (URD) for patients with MDS has been pursued by a number of groups. Early reports were disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/19\">",
"     19",
"    </a>",
"    ]. However, somewhat better results were reported from Seattle where 52 patients with MDS or MDS-related acute leukemia underwent URD HCT: the two-year disease-free survival was 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with MDS-related acute myeloid leukemia had a higher risk of relapse, as expected.",
"   </p>",
"   <p>",
"    In a 1998 report, the European Blood and Marrow Transplantation Group presented data on 118 patients with MDS who received URD HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/21\">",
"     21",
"    </a>",
"    ]. Age was a significant factor in transplant-related mortality, with rates of 40, 61, and 81 percent for patients &lt;18, 18 to 35, and &gt;31 years of age, respectively. The risk of disease relapse was related to the FAB classification at the time of HCT, being 13, 15, 29, and 45 percent for patients with RA, RARS, RAEB, and RAEB-T, respectively. Two-year survival was 28 percent. An update of their transplant experience in 374 patients with RA or RARS and a median age of 39 years indicated no significant difference in four-year overall survival between those receiving HCT from HLA-matched identical siblings or HLA-matched unrelated donors (52 versus 50 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of 510 patients with MDS receiving URD HCT through the National Marrow Donor Program between 1988 and 1998, two-year and four-year disease-free survivals (DFS) averaged 29 and 26 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/23\">",
"     23",
"    </a>",
"    ]. Factors associated with improved DFS included the diagnosis of RA, grade 0 or I acute GVHD, higher cell dose, recipient CMV negativity, transplantation &lt;9 months after diagnosis, and transplantation during the last four years of the study.",
"   </p>",
"   <p>",
"    Cumulative treatment-related mortality (TRM) at two years was 54 percent; factors adversely affecting TRM included increased donor and recipient age, donor-recipient HLA mismatching, patient CMV seropositivity, and grades II-IV acute GVHD. These results confirm that some patients with MDS can enjoy long term disease-free survival and, perhaps, cure; however, because TRM is high, there is much room for improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytogenetic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Karyotype analysis with metaphase cytogenetics is a key component of the initial evaluation of a patient with MDS; specific cytogenetic abnormalities in MDS have considerable prognostic significance and affect treatment planning. These cytogenetic abnormalities have also demonstrated prognostic value in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. While several prognostic scoring systems that incorporate cytogenetics have been developed, we generally rely upon the revised International Prognostic Scoring System (IPSS-R) MDS risk category (",
"    <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"     table 2",
"    </a>",
"    ) to help guide management decisions. The available prognostic scoring systems for MDS are presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The original International Prognostic Scoring System (IPSS) was derived from survival data of patients with primary (de novo) MDS treated primarily with supportive care alone (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/2\">",
"     2",
"    </a>",
"    ]. This prognostic scoring system used information regarding a limited number of specific cytogenetic abnormalities, which were divided into three prognostic categories. Subsequently, the IPSS-R was created based upon data from a much larger cohort of patients with primary MDS (",
"    <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"     table 2",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This allowed for the incorporation of a larger number of specific cytogenetic abnormalities, which were divided into five prognostic categories.",
"   </p>",
"   <p>",
"    The ability of the IPSS and IPSS-R cytogenetic categories to predict outcome following allo-HCT was evaluated in a single center, retrospective study of 1007 patients with MDS or acute leukemia evolving from MDS who underwent related (547 patients) or unrelated (460 patients) allo-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/28\">",
"     28",
"    </a>",
"    ]. The estimated rates of relapse, non-relapse mortality, overall survival, and relapse-free survival at five years were 25, 40, 38, and 35 percent, respectively. Grade 2 to 4 GVHD occurred in 69 percent (26 percent grade",
"    <span class=\"nowrap\">",
"     3/4).",
"    </span>",
"    Chronic GVHD occurred in 40 percent. While both cytogenetic risk stratification schemes provided prognostic information regarding relapse rate and survival after HCT, the five prognostic categories included in the IPSS-R were better able to differentiate among the lowest and highest risk disease. The estimated cumulative incidence of relapse at five years ranged from &lt;20 percent for patients with very good cytogenetics to approximately 50 percent for patients with very poor cytogenetics.",
"   </p>",
"   <p>",
"    In another study, the prognostic value of cytogenetics was evaluated in a series of 60 patients with MDS who underwent allo-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with poor risk cytogenetics, as defined by the original IPSS (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/2\">",
"     2",
"    </a>",
"    ], had a much worse outcome (event-free survival of 6 percent versus 40 to 51 percent for the intermediate and good risk groups) and a significantly higher relapse rate (82 versus 12 to 19 percent).",
"   </p>",
"   <p>",
"    However, cytogenetic risk may correlate with other risk factors. As an example, in a study of 57 patients with MDS, those with del(5q) as the sole chromosomal abnormality had less advanced disease morphology, a lower IPSS scores, and better transplantation outcomes than those with del(5q) and additional karyotypic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Special settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow transplantation has also been evaluated in specific subsets of patients with MDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Older patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study from Seattle evaluated the outcome after HCT (mostly allogeneic) in 50 patients between the ages of 55 and 66 (median 59 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/29\">",
"     29",
"    </a>",
"    ], an important issue since 75 percent of patients with MDS are over age 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/2\">",
"     2",
"    </a>",
"    ]. The estimated three-year survival was 44 percent in 13 patients with RA, 46 percent in 19 patients with RAEB, and 33 percent in 18 patients with",
"    <span class=\"nowrap\">",
"     RAEB-T/AML",
"    </span>",
"    or CMML. Survival in all categories was inversely related to cytogenetic risk classification and IPSS risk score and was highest in patients treated with a protocol in which the plasma",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    concentration was targeted at 600 to 900",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    A",
"    retrospective analysis of 1333 patients with MDS older than 50 years (median age 56, range: 50 to 74 years) who received an allogeneic HCT through the European Group for Blood and Marrow Transplantation since 1998 revealed the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four-year estimated overall survival (OS) of the whole cohort was 31 percent. There were no significant differences in OS between those 50 to 60 (34 percent) or greater than 60 (27 percent) or for those who received reduced intensity (RIC, 32 percent) or standard conditioning (30 percent). Risk factors for reduced OS included advanced disease at the time of HCT and poor risk cytogenetics.",
"     </li>",
"     <li>",
"      Four-year estimated non-relapse mortality (NRM) was 36 percent for the entire group. Risk factors for increased NRM included use of standard conditioning, use of an unrelated donor, and advanced disease at the time of HCT.",
"     </li>",
"     <li>",
"      Four-year rates of relapse were significantly higher in those receiving RIC (41 percent) than in those receiving standard conditioning (33 percent). Other risk factors for relapse included advanced disease at the time of HCT and poor risk cytogenetics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, HCT can be successful in selected patients in this age group, although nonrelapse mortality from the procedure is high, being approximately 40 percent at two to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The use of non-myeloablative transplantation for older patients with this disorder is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Nonmyeloablative or reduced intensity regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment-related MDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-related (t)-MDS is an extremely serious complication of cytotoxic chemotherapy that is invariably fatal with standard treatments.",
"   </p>",
"   <p>",
"    A report from Seattle described results of related or unrelated hematopoietic stem cell transplantation in 56 patients with treatment-related AML and 55 with t-MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/32\">",
"     32",
"    </a>",
"    ]. Five-year disease-free survival and nonrelapse mortality were strongly dependent on the conditioning regimen used, being 8 and 58 percent for total body irradiation and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (CY), 19 and 52 percent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    (BU) and CY, and 30 and 42 percent for targeted BU and CY, respectively. The five-year cumulative incidence of relapse was 40 percent for patients with AML or RAEB-t, 26 percent for those with RAEB, and zero percent for those with RA or RARS. Of interest, disease-free survival, relapse, and nonrelapse mortality did not appear to be affected by the primary diagnosis or whether the donor was related or unrelated.",
"   </p>",
"   <p>",
"    In a second report of allo-HCT in 31 patients with treatment-related MDS, all of whom were &lt;60 years of age, two-year event free survival was 50, 43, and 16 percent for patients with low, intermediate, and high IPSS risk scores (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/33\">",
"     33",
"    </a>",
"    ]. The presence of complex karyotypes or chromosome 7 abnormalities increased the rate of relapse and reduced event-free survival, while attainment of a complete remission with induction chemotherapy before allo-HCT was associated with improved disease-free survival and a reduced rate of relapse. Treatment related mortality for this group of patients was 49 percent.",
"   </p>",
"   <p>",
"    In a later report from Seattle, which included outcomes in 257 patients with secondary MDS or transformation to AML (t-AML), five-year relapse-free survival was highest (43 percent) and non-relapse mortality lowest (28 percent) among those whose conditioning regimens included",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"      busulfan",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"    </span>",
"    with busulfan targeting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/34\">",
"     34",
"    </a>",
"    ]. Outcomes were similar for those with secondary",
"    <span class=\"nowrap\">",
"     MDS/t-AML",
"    </span>",
"    when compared with a group of 339 patients transplanted for primary",
"    <span class=\"nowrap\">",
"     MDS/t-AML.",
"    </span>",
"    For both groups, probability of relapse and relapse-free survival correlated with disease stage and karyotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allo-HCT is the treatment of choice for MDS in children and has resulted in long term survival for a significant percentage of those with HLA-matched sibling donors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. As an example, the Seattle group transplanted six children with MDS under the age of two years; all were alive more than 1.5 years later [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/37\">",
"     37",
"    </a>",
"    ]. A larger cohort of 94 children transplanted between 1976 and 2001 resulted in three-year probabilities of OS and EFS of 50 and 41 percent, respectively. Children with the MDS subgroups RA and RARS fared particularly well, with an estimated three-year survival rate of 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This subject is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=see_link\">",
"     \"Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Chronic myelomonocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic myelomonocytic leukemia (CMML) generally have a poor prognosis with little effective therapy. Allo-HCT has been explored for children and adults with this disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two studies, five- to 10-year disease-free survival was approximately 40 percent for children with HLA-matched sibling donors, which was felt to be superior to other forms of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Seattle experience with allo-HCT in 21 CMML patients (median age 47 years, range: 1 to 63) indicated an estimated disease-free survival of 39 percent at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/41\">",
"       41",
"      </a>",
"      ]. There was a suggestion of an improved probability of survival in those patients with shorter disease duration prior to transplant. Similar results were obtained from another single-center report in 18 patients (three-year overall survival of 31 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Results in 50 adults (median age 44, range: 19 to 61) treated with allo-HCT and reported through the European Group for Blood and Marrow Transplantation indicated a treatment-related mortality of 52 percent, with an estimated five-year disease-free survival of 18 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few studies have explored the use of non-myeloablative or reduced intensity allogeneic transplantation in CMML, as well as in the other forms of MDS, which may be especially attractive early in the course of the disease. Preliminary results, including a low transplant-related mortality and a possible graft-versus-leukemia effect, have been promising and require further follow-up and treatment of more patients (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Nonmyeloablative or reduced intensity regimens'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/17,44-46\">",
"     17,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Evolution into acute leukemia prior to HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most transplant series of patients with MDS have included patients with MDS evolving into acute myeloid leukemia (AML) prior to HCT. However, due to the extremely poor outcome and difficulty in successfully inducing patients into remission, many transplant centers prefer to proceed directly to transplantation without prior antileukemic chemotherapy, which is only relevant for patients able to tolerate myeloablative conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, treatment of",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    patients with chemotherapy increases the risk of developing further complications of immunosuppression, namely infection, especially fungal disease, and organ damage.",
"   </p>",
"   <p>",
"    In a small study, 13 adult patients with MDS-related AML or RAEB (age range: 20 to 51 years) were treated with total body irradiation, cytosine arabinoside,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , followed by unrelated, HLA-mismatched umbilical cord blood transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/48\">",
"     48",
"    </a>",
"    ]. The probability of disease-free survival at two years was 76 percent. Further follow-up continued to be favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients being considered for non-myeloablative allo-HCT, those with &gt;10 percent bone marrow blasts have fared relatively poorly due to disease recurrence and transplant related complications. These patients generally are first either treated with chemotherapy or a hypomethylating agent (eg, 5-azacytidine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]) prior to initiating the transplant procedure. Other agents may also prove to be effective in reducing the disease burden prior to non-myeloablative allogeneic transplantation (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Nonmyeloablative or reduced intensity regimens'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     T cell depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell depleted grafts have been explored in an attempt to lower transplant-related mortality by reducing the incidence of GVHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    .) In one study of 35 patients with a median age of 40 years (range 23 to 60) treated in this manner, the probability of disease-free survival at two years was 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/53\">",
"     53",
"    </a>",
"    ]. This uncontrolled value is not better than those described above in which T cell depletion was generally not performed.",
"   </p>",
"   <p>",
"    The rabbit anti-T cell antiserum thymoglobulin has also been added to the targeted",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"      busulfan",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"    </span>",
"    regimen with an apparent reduction in acute and chronic GVHD risk for patients who received between 4.5 and 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of thymoglobulin, as compared with historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MDS are chronically immunosuppressed and are at risk for a variety of occult infections. They are also at high risk for relapse (as much as 40 percent at five years) following the treatment procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/9\">",
"     9",
"    </a>",
"    ]. Small numbers of patients who have relapsed have undergone donor leukocyte infusions in an attempt to utilize the graft-versus-disease effect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Durable responses are not attained in most patients with MDS and grade II to IV GVHD is common [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NONMYELOABLATIVE OR REDUCED INTENSITY REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of less toxic and better tolerated nonmyeloablative or reduced intensity conditioning (RIC) regimens may allow allo-HCT to be performed in patients with MDS and advanced age or co-morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/17,44,46,58-65\">",
"     17,44,46,58-65",
"    </a>",
"    ], with the hope that such regimens would result in lower rates of treatment-related mortality (TRM) without sacrificing relapse-free (RFS) and overall survival (OS), and with a reasonable balance between GVHD and the graft-versus-tumor effect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The balance between TRM, RFS, and OS using RIC or myeloablative conditioning was evaluated in a retrospective analysis that compared these three outcomes following HLA-identical sibling donor allo-HCT in 836 patients with MDS. Of these, 215 patients received RIC and 621 myeloablative conditioning. The following outcomes were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment-related mortality at three years was significantly lower in those receiving RIC (22 versus 32 percent; hazard ratio 0.61; 95% CI 0.41-0.91).",
"     </li>",
"     <li>",
"      The cumulative incidence of relapse at three years was significantly higher in those receiving RIC (45 versus 27 percent; hazard ratio 1.64; 95% CI 1.2-2.2).",
"     </li>",
"     <li>",
"      The increase in relapse following RIC offset its reduced TRM, such that three-year progression-free and overall survival were not significantly different between the two conditioning approaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Variations on the use of reduced intensity conditioning were evaluated in a number of studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study employed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      conditioning in 62 patients with MDS (age range: 22 to 70 years), followed by matched sibling or matched unrelated donor allo-HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/46\">",
"       46",
"      </a>",
"      ]. Non-relapse mortality at 100 days was zero and 11 percent for HLA-identical sibling and matched unrelated transplants, respectively, with predicted one-year disease-free survivals of 61 and 59 percent, respectively. Patients with poor risk cytogenetics or poor risk IPSS scores (",
"      <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"       table 1",
"      </a>",
"      ) at presentation and those with chemoresistant disease had a poor outcome following either reduced-intensity or standard intensity transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/46,61\">",
"       46,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and low dose total body irradiation (200 rad) has been explored in 148 patients with MDS related illnesses. With a median follow-up of 47 months, the three-year relapse-free survival and OS were 27 percent with a relapse incidence of 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A regimen including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      followed by allogeneic HCT was utilized in 19 older patients (median age 64 years) with poor-prognosis myeloid leukemias. GVHD prophylaxis included CSA, MTX or MMF, with ATG for recipients of unrelated grafts. At a median follow-up of approximately two years, 13 of 19 patients were alive with a one-year survival rate of 68 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/62\">",
"       62",
"      </a>",
"      ]. Further follow-up of a total of 34 patients continued to be favorable, with an OS rate of 63 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another reduced intensity regimen (treosulphan,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , ATG) was used to treat 26 patients with secondary",
"      <span class=\"nowrap\">",
"       AML/MDS.",
"      </span>",
"      The median age was 60 years (range 44 to 70). The two-year estimated OS and DFS were 36 and 34 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A novel regimen including photopheresis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      , and TBI (600 cGy) was utilized to treat 18 MDS patients ineligible for standard myeloablative regimens. Sixteen of the 18 patients developed full donor chimerism with no mortality during the first 100 days. Grade II-IV acute GVHD developed in only 19 percent of the patients. At a median follow-up of 14 months, one-year OS was 65 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies demonstrate that non-myeloablative transplantation is feasible for patients with MDS who are generally beyond ages typically considered for myeloablative conditioning. However, further follow-up is required to assess the overall impact of this treatment approach. Particular issues include the risk of disease relapse, which appears to be higher than that observed for patients with acute leukemia who undergo reduced intensity conditioning. Most studies require that patients have a low disease burden as assessed by bone marrow myeloblasts of 5 to 10 percent or less before proceeding with RIC allotransplantation for this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Effect of dose density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have attempted to address the question of how important dose intensity is in the treatment of MDS prior to allogeneic HCT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the outcomes of 94 patients treated with non-myeloablative versus reduced intensity preparative regimens were compared retrospectively. The more dose intensive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      -based regimen was associated with a higher degree of donor cell engraftment, higher treatment-related mortality, and reduced relapse risk [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another retrospective analysis of 836 MDS patients who underwent allo-HCT with an HLA-identical sibling donor and received either a reduced intensity regimen (215 patients) or standard myeloablative conditioning (621 patients) resulted in similar three-year progression-free survivals of 39 and 33 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were observed in another study of 112 MDS patients in which non-relapse mortality was higher following myeloablative conditioning [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/70\">",
"       70",
"      </a>",
"      ]. However, the relapse rate was lower and overall outcome similar.",
"     </li>",
"     <li>",
"      In another retrospective analysis of 265 patients with MDS who had undergone allo-HCT, reduced intensity (130 patients) and myeloablative (33 patients) conditioning resulted in similar rates of overall survival (47 versus 50 percent), event-free survival (42 versus 45 percent), relapse (37 percent each), and non-relapse mortality (22 versus 18 percent) at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/71\">",
"       71",
"      </a>",
"      ]. In addition, a comparison of the 98 patients who received induction chemotherapy and the 48 patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      therapy without induction chemotherapy prior to HCT revealed similar clinical outcomes. In contrast, the 17 patients who received both azacitidine and induction chemotherapy prior to HCT had inferior event-free and overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These retrospective studies suggest that increased dose density reduces relapse risk but is associated with increased non-relapse mortality following allo-HCT. To date there are no prospective randomized comparisons of these two approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15217916\">",
"    <span class=\"h1\">",
"     AUTOLOGOUS HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation (auto-HCT) has been considered for patients with MDS. However, it has been evaluated in limited numbers of patients due to the low complete remission rates obtained with induction chemotherapy. Thus, any positive results must be tempered by the fact that these patients are highly selected.",
"   </p>",
"   <p>",
"    Another approach is in vivo mobilization of peripheral blood progenitor cells, which has been attempted in small numbers of patients with defined karyotypic abnormalities. In one report, nine patients received an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    -containing regimen (mini-ICE protocol: idarubicin 8",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day IV on days 1 to 3,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by two-hour IV infusion on days 1 to 3, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day on days 1 to 3, followed by rhG-CSF). The first leukapheresis was performed as they were recovering from aplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/72\">",
"     72",
"    </a>",
"    ]. Six of the patients had leukapheresis products that were karyotypically normal.",
"   </p>",
"   <p>",
"    The results that been obtained with auto-HCT are illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from the EBMT, 79 patients with MDS or secondary AML were successfully induced into complete remission (CR) and then underwent auto-HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/73\">",
"       73",
"      </a>",
"      ]. Two-year disease-free survival (DFS) was 39 percent. In an update of their experience in 173 patients, three-year DFS was 33 and 18 percent for those transplanted in first CR or beyond first CR, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/4\">",
"       4",
"      </a>",
"      ]. On multivariate analysis, transplantation in CR1 and younger age favorably influenced overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from France, 42 of 83 patients under the age of 55 with high-risk MDS achieved complete remission after chemotherapy and were considered for autologous transplantation with bone marrow or peripheral blood stem cells following a preparative regimen of",
"      <span class=\"nowrap\">",
"       BU/CY",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/75\">",
"       75",
"      </a>",
"      ]. Twenty-four patients were eventually transplanted; all achieved hematological reconstitution. Three patients died from the procedure and nine relapsed. The remaining 12 patients (50 percent of the transplanted patients but only 14 percent of the initial cohort) were in complete remission after 8 to 55 months of follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 15 percent of patients enjoyed long term survival, with some patients in continued CR 5 to 10 years from transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/39/8826/abstract/76\">",
"     76",
"    </a>",
"    ]. Therefore, a small but identifiable percentage of patients achieving CR may benefit from autologous HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no agreed upon standard treatment approach for patients with symptomatic myelodysplastic syndrome (MDS) and patients should be encouraged to enroll in clinical trials whenever available. Our treatment approach incorporates knowledge of the patient&rsquo;s performance status, the revised International Prognostic Scoring System (IPSS-R) MDS risk category (",
"      <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"       table 2",
"      </a>",
"      ), to help guide management decisions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link\">",
"       \"Overview of the treatment of myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to all other treatment modalities, a subset of patients with MDS can be cured following allogeneic hematopoietic cell transplantation (allo-HCT). Allo-HCT may be considered for patients with MDS &lt;60 years of age with an HLA-matched sibling donor or a well matched unrelated donor. The decision to pursue this aggressive form of therapy depends upon a number of criteria including the original or revised International Prognostic Scoring System MDS risk category (",
"      <a class=\"graphic graphic_table graphicRef66149 \" href=\"UTD.htm?14/5/14427\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"       table 2",
"      </a>",
"      ), risk of disease progression, risk of infection, overall health of the patient, and the willingness of the patient to take on the risks associated with allo-HCT. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Allogeneic HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a high (&gt;4.5 to 6 points) or very high (&gt;6 points) IPSS-R score who are eligible for allo-HCT and have an available related or unrelated matched donor, we recommend high intensity chemotherapy followed by allo-HCT. If a donor is not available, these patients may be treated with intensive induction therapy alone such as that used for acute myeloid leukemia (AML) or with a DNA hypomethylating agent with plans to treat with intensive induction therapy at the time of AML transformation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=see_link&amp;anchor=H48546547#H48546547\">",
"       \"Treatment of high or very high risk myelodysplastic syndromes\", section on 'Hematopoietic cell transplantation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=see_link&amp;anchor=H48546554#H48546554\">",
"       \"Treatment of high or very high risk myelodysplastic syndromes\", section on 'High intensity chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment options for patients with an intermediate risk (&gt;3 to 4.5 points) IPSS-R score include those used for patients with low or very low risk IPSS-R scores and the more intensive therapies typically used for patients with high or very high risk IPSS-R scores. A choice among these treatments must take into consideration the patient&rsquo;s values and preferences and their interpretation of what constitutes a reasonable survival and reasonable risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H17341115#H17341115\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Intermediate risk IPSS-R'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a very low (&le;1.5 points) or low (&gt;1.5 to 3 points) IPSS-R score are primarily treated with supportive care or low intensity therapies, such as DNA hypomethylating agents or immunosuppressive therapy. This approach is also appropriate for patients with a low (0 points) or intermediate-1 (0.5 to 1.0 points) risk IPSS score. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H519324#H519324\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Choice of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-myeloablative allogeneic HCT appears promising for patients with MDS who are not candidates for myeloablative allo-HCT. Early results are encouraging in terms of reduced treatment-related mortality, although significant problems remain (eg, increased relapse risk). Patients should be enrolled in well-designed clinical trials attempting to address the important issues of patient comorbidities, reducing transplant-related complications, graft-versus-host disease, and relapse risk. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonmyeloablative or reduced intensity regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/1\">",
"      Benesch M, Deeg HJ. Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 2003; 78:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/2\">",
"      Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/3\">",
"      Kr&ouml;ger N, Brand R, van Biezen A, et al. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. Bone Marrow Transplant 2005; 35:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/4\">",
"      de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/5\">",
"      Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/6\">",
"      Appelbaum FR, Barrall J, Storb R, et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 1990; 112:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/7\">",
"      Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/8\">",
"      Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 2002; 8:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/9\">",
"      Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/10\">",
"      O'Donnell MR, Nademanee AP, Snyder DS, et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 5:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/11\">",
"      Bunin NJ, Casper JT, Chitambar C, et al. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. J Clin Oncol 1988; 6:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/12\">",
"      Longmore G, Guinan EC, Weinstein HJ, et al. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol 1990; 8:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/13\">",
"      O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/14\">",
"      Ratanatharathorn V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/15\">",
"      Sierra J, P&eacute;rez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/16\">",
"      Fujimaki K, Taguchi J, Fujita H, et al. Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 2004; 33:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/17\">",
"      Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/18\">",
"      Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89:3055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/19\">",
"      Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/20\">",
"      Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 1996; 93:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/21\">",
"      Arnold R, de Witte T, van Biezen A, et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998; 21:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/22\">",
"      de Witte T, Brand R, van Biezen A, et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 2009; 146:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/23\">",
"      Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/24\">",
"      Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/25\">",
"      Stewart B, Verdugo M, Guthrie KA, et al. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. Br J Haematol 2003; 123:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/26\">",
"      Schanz J, T&uuml;chler H, Sol&eacute; F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/27\">",
"      Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/28\">",
"      Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/29\">",
"      Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000; 95:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/30\">",
"      Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/31\">",
"      Wallen H, Gooley TA, Deeg HJ, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/32\">",
"      Witherspoon RP, Deeg HJ, Storer B, et al. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001; 19:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/33\">",
"      Yakoub-Agha I, de La Salmoni&egrave;re P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/34\">",
"      Chang C, Storer BE, Scott BL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/35\">",
"      Locatelli F, Pession A, Bonetti F, et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994; 8:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/36\">",
"      Rubie H, Attal M, Demur C, et al. Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes. Bone Marrow Transplant 1994; 13:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/37\">",
"      Woolfrey AE, Gooley TA, Sievers EL, et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood 1998; 92:3546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/38\">",
"      Yusuf U, Frangoul HA, Gooley TA, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004; 33:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/39\">",
"      Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997; 89:3534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/40\">",
"      Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/41\">",
"      Zang DY, Deeg HJ, Gooley T, et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000; 110:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/42\">",
"      Krishnamurthy P, Lim ZY, Nagi W, et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant 2010; 45:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/43\">",
"      Kr&ouml;ger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/44\">",
"      Taussig DC, Davies AJ, Cavenagh JD, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003; 21:3060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/45\">",
"      Davies JK, Taussig DC, Oakervee H, et al. Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease. J Clin Oncol 2006; 24:e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/46\">",
"      Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/47\">",
"      Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/48\">",
"      Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101:4711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/49\">",
"      Ooi J. The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 2006; 47:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/50\">",
"      De Padua Silva L, de Lima M, Kantarjian H, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009; 43:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/51\">",
"      Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/52\">",
"      Cogle CR, Imanirad I, Wiggins LE, et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 2010; 8:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/53\">",
"      Mattijssen V, Schattenberg A, Schaap N, et al. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant 1997; 19:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/54\">",
"      Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/55\">",
"      Tsuzuki M, Maruyama F, Kojima H, et al. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/56\">",
"      Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/57\">",
"      Okumura H, Takamatsu H, Yoshida T. Donor leucocyte transfusions for relapse in myelodyplastic syndrome after allogeneic bone marrow transplantation. Br J Haematol 1996; 93:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/58\">",
"      Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89:4531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/59\">",
"      Lim ZY, Ho AY, Ingram W, et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006; 135:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/60\">",
"      Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/61\">",
"      Parker JE, Shafi T, Pagliuca A, et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002; 119:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/62\">",
"      Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/63\">",
"      Spyridonidis A, Bertz H, Ihorst G, et al. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (&gt; or = 60 years) with active myeloid malignancies. Blood 2005; 105:4147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/64\">",
"      Kr&ouml;ger N, Shimoni A, Zabelina T, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006; 37:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/65\">",
"      Chan GW, Foss FM, Klein AK, et al. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/66\">",
"      Valc&aacute;rcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/67\">",
"      Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/68\">",
"      de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/69\">",
"      Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108:2928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/70\">",
"      Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/71\">",
"      Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Moelle et de Th&eacute;rapie-Cellulaire and the Groupe-Francophone des My&eacute;lodysplasies. J Clin Oncol 2012; 30:4533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/72\">",
"      Carella AM, Dejana A, Lerma E, et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 1996; 95:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/73\">",
"      De Witte T, Van Biezen A, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 1997; 90:3853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/74\">",
"      Kr&ouml;ger N, Brand R, van Biezen A, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006; 37:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/75\">",
"      Wattel E, Solary E, Leleu X, et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Fran&ccedil;ais des My&eacute;lodysplasies. Group Ouest-Est d'&eacute;tude des Leuc&eacute;mies aigu&euml;s my&eacute;lo&iuml;des. Leukemia 1999; 13:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/39/8826/abstract/76\">",
"      Ducastelle S, Ad&egrave;s L, Gardin C, et al. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Haematologica 2006; 91:373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3547 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5DB5CB92DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8826=[""].join("\n");
var outline_f8_39_8826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ALLOGENEIC HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15218057\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Matched unrelated donor allo-HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytogenetic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Special settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Older patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment-related MDS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Chronic myelomonocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Evolution into acute leukemia prior to HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NONMYELOABLATIVE OR REDUCED INTENSITY REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Effect of dose density",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15217916\">",
"      AUTOLOGOUS HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3547|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/37/27228\" title=\"table 1\">",
"      IPSS in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/16/20749\" title=\"table 2\">",
"      IPSS-R in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/5/14427\" title=\"table 3\">",
"      Survival MDS by IPSS and age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=related_link\" title=\"calculator 1\">",
"      Calculator: Myelodysplastic syndrome international prognostic scoring system (Original IPSS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=related_link\" title=\"calculator 2\">",
"      Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=related_link\">",
"      Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=related_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=related_link\">",
"      Prognosis of the myelodysplastic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=related_link\">",
"      Treatment of high or very high risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_39_8827="LEVO LV dose adjustment";
var content_f8_39_8827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for dose adjustment with LEVOleucovorin (l-isomer of leucovorin) for prolonged methotrexate excretion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Plasma methotrexate (MTX) level",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose and/or schedule adjustment for l-leucovorin (LEVO leucovorin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &lt;50 micromolar at 24 hours",
"      </td>",
"      <td>",
"       7.5 mg IV every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;50 micromolar at 24 hours",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        75 mg IV every 3 hours until MTX level &lt;1 micromolar.",
"       </p>",
"       <p>",
"        Then, 7.5 mg IV every 3 hours until MTX level &lt;0.05 micromolar.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;5 micromolar at 48 hours",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       100 percent or greater increase in serum creatinine level at 24 hours after MTX administration",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8827=[""].join("\n");
var outline_f8_39_8827=null;
var title_f8_39_8828="Food intolerances IBD PI";
var content_f8_39_8828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Foods and beverages that may worsen gastrointestinal symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Milk, milk-containing products, and lactose-free milk products, including ice cream, cream cheese, cheese, cottage cheese, yogurt, pudding, whipped cream, cream, cheesecake, chocolate, pastries, crackers, pretzels, cookies, crackers, cakes, and pies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Caffeine-containing products, including coffee, tea, and sodas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcohol products",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fruits and fruit juices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spices, seasonings, and spicy marinades",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diet beverages, diet foods, diet candies, diet gum, sugar-free products",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fried foods, fatty foods, fast foods, and Chinese food",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Condiments including ketchup, mustard, mayonnaise, and relish",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Whole-grain or multigrain breads; sourdough breads, bagels, and yeast-containing products",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salads, particularly added components including bacon bits, croutons, onions, and peppers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salad dressings that contain mayonnaise, cheese, and spices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vegetables including cabbage, broccoli, and cauliflower",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Legumes: beans, lentils, chili",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Red meats including steak, hamburger, sausage, bacon, and prime rib",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gravies, spaghetti sauce, soups, stews, and stuffing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Popcorn, peanuts, corn",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Artificial colorings, flavorings, and sweeteners",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Foods and beverages containing sorbitol, fructose, or high-fructose corn syrup",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The foods and drinks listed above may worsen gastrointestinal symptoms (diarrhea, cramps, abdominal pain, nausea, gas, bloating, heartburn, etc.) in some patients with both irritable bowel syndrome and inflammatory bowel disease. These symptoms can begin as soon as 5 to 15 minutes after eating or as many as 12 to 48 hours later.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: MacDermott, RP. Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis 2007; 13:91.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8828=[""].join("\n");
var outline_f8_39_8828=null;
var title_f8_39_8829="Causes chylous ascites";
var content_f8_39_8829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of chylous ascites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neoplastic (common in adults)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other cancers (see text)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphangiomyomatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carcinoid tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kaposi's sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cirrhosis (common in adults)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Congenital (common in children)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary lymphatic hypoplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Yellow nail syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Klippel-Trenaunay syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Primary lymphatic hyperplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bilateral hyperplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Intestinal lymphangiectasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Postoperative",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Abdominal aneurysm repair",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retroperitoneal node dissection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Catheter placement for peritoneal dialysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inferior vena cava resection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Laparoscopic nissen fundoplication",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Right heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dilated cardiomyopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nephrotic syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Filariasis (Wuchereria bancrofti)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mycobacterium avium intracellulare",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Constrictive pericarditits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retroperitoneal fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Celiac sprue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Whipple's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retractile mesenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blunt abdominal trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Battered child syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8829=[""].join("\n");
var outline_f8_39_8829=null;
var title_f8_39_8830="Contents: Spondyloarthropathies";
var content_f8_39_8830=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Spondyloarthropathies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Spondyloarthropathies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ankylosing spondylitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35194\">",
"           Assessment and treatment of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/9/151\">",
"           Clinical manifestations of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/20/13640\">",
"           Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/23/17782\">",
"           General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Arthritis and bowel disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25289\">",
"           Arthritis associated with gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/14/6377\">",
"           Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Behcet's disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/18/298\">",
"           Clinical manifestations and diagnosis of Beh������et���������s disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psoriatic arthritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/49/30488\">",
"           Clinical manifestations and diagnosis of psoriatic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/3/23608\">",
"           Pathogenesis of psoriatic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/18/40234\">",
"           Treatment of psoriatic arthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reactive arthritis and undifferentiated spondyloarthropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12090\">",
"           Pathogenesis of spondyloarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/27/33210\">",
"           Reactive arthritis (formerly Reiter syndrome)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Undifferentiated spondyloarthropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/57/9114\">",
"           Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12090\">",
"           Pathogenesis of spondyloarthritis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-D96F5015BF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_39_8830=[""].join("\n");
var outline_f8_39_8830=null;
var title_f8_39_8831="Electron beam computed tomography scan of aortic dissection";
var content_f8_39_8831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron beam computed tomography scan of aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single electron beam computed tomography scan of the ascending and descending aorta showing a clear \"flap\" in the ascending aorta. This finding is consistent with a type A aortic dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_39_8831=[""].join("\n");
var outline_f8_39_8831=null;
